Translation of the instructions can be
STREPTOCYD liniment 5%
Instruction
For medical use of the drug
Streptocide
(Streptocidum)
Composition:
1 g of liniment contains:
active ingredient: sulfonamide (streptocide) 50 mg;
excipients: purified fish oil for external use, butylhydroxyanisole (E 320), emulsifier No. 1, polysorbate-80 or purified sodium carboxymethylcellulose, purified water;
excipients that are part of emulsifier No. 1: cetyl alcohol, stearyl alcohol.
Dosage form.
Liniment.
Main physicochemical properties: liniment of white color with a yellowish or yellow-brown tint, with a specific odor.
Pharmacotherapeutic group.
Chemotherapeutic agents for topical use. Sulfonamides. ATC code d06b A05.
Pharmacological properties.
Pharmacodynamics.
The drug has an antimicrobial effect on streptococci and other microorganisms. Streptocide disrupts the process of assimilation by the microbial cell of its growth factors - folic, dihydrofolic acids and other compounds that contain para-aminobenzoic acid (PABA). Due to the similarity of the chemical structure of PABA and sulfonamide, the latter, as a competitive antagonist of the acid, is included in the metabolism of microorganisms and disrupts it.
Pharmacokinetics.
Didn't study.
Clinical characteristics.
Indication.
Ulcers, burns, cracks, wounds, pyoderma, erysipelas, purulent-inflammatory skin processes that are not accompanied by pronounced exudation, infected wounds in the regeneration stage.
Contraindication.
Hypersensitivity to the components of the drug or to any other sulfonamides. Renal failure, acute porphyria. Pregnancy or breastfeeding.
Special safety measures.
If an allergic reaction occurs at the site of application of the liniment, the use of the drug should be discontinued.
Premature discontinuation of treatment with the drug may cause the development of microorganisms resistant to sulfonamides.
Interaction with other drugs and other types of interactions.
While using streptocide, it is undesirable to take drugs such as digitoxin, hydrochloric acid, caffeine, mezaton, phenobarbital, and adrenaline hydrochloride.
Novocaine, which contains a para-aminobenzoic acid residue, reduces the effectiveness of the drug if these drugs are used immediately one after the other.
Application features.
Use during pregnancy or breastfeeding.
Do not use.
The ability to influence the reaction speed when driving or working with other mechanisms.
Does not affect.
Method of administration and doses.
Liniment should be applied in a thin layer to the affected area, including under a gauze bandage. The frequency and duration of application depends on the severity of the disease, the achieved therapeutic effect and is determined by the doctor individually.
Children.
The safety and effectiveness of streptocide in children have not been established, so the drug should not be prescribed to this age group of patients.
Overdose.
Overdose may increase the side effects of the drug.
Treatment: therapy is symptomatic.
Adverse reactions.
In case of hypersensitivity to sulfonamides, local allergic reactions (including dermatitis, urticaria) are possible, the development of which requires immediate discontinuation of the drug.
Expiration date.
2 years.
Storage conditions.
Store in original packaging at a temperature not exceeding 25 0C.
Freezing is not allowed.
Keep out of reach of children.
After opening the tube, store the drug for the duration of the course of treatment.
Packaging.
30 g in tubes No. 1.
Vacation category.
Without a prescription.
Producer.
PJSC Lubnyfarm.
Location of the manufacturer and address of its place of business.
Ukraine, 37500, Poltava region, M lubny, Barvinkovy St., 16.
STREPTOCID ointment 10%
Instruction
For medical use of the medicinal product
Streptocide
(Streptocidum)
Composition:
Active ingredient: 1 g of ointment contains sulfonamide 100 mg;
excipients: white soft paraffin, mineral oil.
Dosage form.
Ointment.
Main physicochemical properties: homogeneous thick mass of white or light yellow color.
Pharmacotherapeutic group.
Chemotherapeutic agents for topical use. sulfonamides.
PBX code D06B A05.
Pharmacological properties.
Pharmacodynamics.
The drug has an antimicrobial effect on streptococci and other microorganisms. Streptocide disrupts the process of assimilation by the microbial cell of its growth factors - folic, dihydrofolic acids and other compounds that contain para-aminobenzoic acid (PABA). Due to the similarity of the chemical structure of PABA and sulfonamide, the latter, as a competitive antagonist of the acid, is included in the metabolism of microorganisms and disrupts it.
Clinical characteristics.
Indication.
Ulcers, burns, cracks, wounds, pyoderma, erysipelas, purulent-inflammatory skin processes that are not accompanied by pronounced exudation, infected wounds in the regeneration stage.
Contraindication.
Hypersensitivity to the components of the drug or to any other sulfonamide drugs.
Renal failure, acute porphyria.
Special safety measures.
Premature discontinuation of treatment with the drug may cause the development of microorganisms resistant to sulfonamides.
Interaction with other drugs and other types of interactions.
While using streptocide ointment, it is undesirable to take such drugs as digitoxin, hydrochloric acid, caffeine, mezaton, phenobarbital, adrenaline hydrochloride. Novocaine, which contains a para-aminobenzoic acid residue, reduces the effectiveness of the drug if these drugs are used immediately one after the other.
Application features.
Use during pregnancy or breastfeeding.
The drug is contraindicated.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Does not affect.
Method of administration and doses.
Streptocide, ointment, is applied in a thin layer to the affected area, including under a gauze bandage. The frequency and duration of application depends on the severity of the disease, the achieved therapeutic effect and is determined by the doctor.
Children.
The safety and effectiveness of streptocide in children have not been established, therefore the drug is not recommended for use in this age group of patients.
Overdose.
Overdose may increase the side effects of the drug.
Treatment: symptomatic therapy.
Adverse reactions.
In case of hypersensitivity to sulfonamides, local allergic reactions are possible, including dermatitis and urticaria, the development of which requires immediate discontinuation of the drug.
Expiration date.
5 years.
Storage conditions.
Store in original packaging at a temperature of 8 °C to 15 °C.
Keep out of reach of children.
Packaging.
25 g in tubes No. 1 or jars.
Vacation category.
Without a prescription.
Producer.
PJSC Lubnyfarm.
Location of the manufacturer and address of its place of business.
Ukraine, 37500, Poltava region, M lubny, ul. Barvinkova, 16.
STREPTOCYD tablets 300 mg
Instruction
For medical use of the medicinal product
Streptocide
(Streptocidum)
Composition:
Active ingredient: sulfanilamide;
1 tablet contains streptocide (sulfanilamide) 300 mg;
excipients: potato starch, talc.
Dosage form.
Pills.
Main physicochemical properties: solid, regular, round cylinders, the upper and lower surfaces of which are flat, the edges of the surfaces are beveled, with a dividing line, white or almost white in color.
Pharmacotherapeutic group.
Antibacterials for systemic use. Short-acting sulfonamides. ATC code j01e b06.
Pharmacological properties.
Pharmacodynamics.
Streptocide disrupts the formation of so-called "germ factors" in microorganisms - folic, dehydrofolic acids, other compounds that have para-aminobenzoic acid (PABA) in their molecule. Due to the proximity of the structures of PABA and Streptocide, sulfonamide, as a competitive antagonist of the acid, is included in the metabolic chain of microorganisms and disrupts the metabolic processes in it, which leads to a bacteriostatic effect. Streptocide is a short-acting sulfonamide, has a bacteriostatic effect on streptococci, meningococci, pneumococci, gonococci, Escherichia coli, pathogens of toxoplasmosis and malaria. Does not affect anaerobic microorganisms.
Pharmacokinetics.
When administered internally, it is rapidly absorbed - the maximum concentration of streptocide in the blood is observed after 1-2 hours (more than 4 hours are indicated in the cerebrospinal fluid); a decrease in the maximum concentration in the blood by 50% occurs in less than 8 hours. Approximately 95% of the drug is excreted by the kidneys.
Clinical characteristics.
Indication.
Infectious-inflammatory diseases caused by microorganisms sensitive to the drug: infectious diseases of the skin and mucous membranes (wounds, ulcers, bedsores), enterocolitis, pyelitis, cystitis.
Contraindication.
Individual sensitivity to sulfonamides, sulfones or other components of the drug; history of severe toxic-allergic reactions to sulfonamides; suppression of bone and hematopoiesis; uncompensated heart failure; diseases of the hematopoietic system; anemia; leukopenia; Graves' disease; kidney and liver diseases (nephrosis, nephritis, liver failure, severe renal failure, acute hepatitis); hyperthyroidism; congenital deficiency of glucose-6-phosphate dehydrogenase; azotemia; porphyria.
When used simultaneously:
with nonsteroidal anti-inflammatory drugs, sulfonylurea derivatives, antithrombotic agents, vitamin K antagonists - the effect of these drugs is enhanced; with folic acid, bactericidal antibiotics (including penicillins, cephalosporins) - the effectiveness of sulfonamides is reduced; with bactericidal antibiotics, oral contraceptives - the effect of these drugs is reduced; with para-aminosalicylic acid and barbiturates - the activity of sulfonamides is enhanced; with erythromycin, lincomycin, tetracycline - the antibacterial activity is mutually enhanced, the spectrum of action is expanded; with rifampicin, streptomycin, monomycin, kanamycin, gentamicin, oxyquinoline derivatives (nitroxoline) - the antibacterial effect of the drugs does not change; with nalidixic acid (nevigramon) - sometimes antagonism is observed; with chloramphenicol, nitrofurans - the total effect is reduced; with drugs containing para-aminobenzoic acid esters (novocaine, anestezin, dicamine), - the antibacterial activity of sulfonamides is inactivated.
Sulfonamides are not prescribed simultaneously with hexamethylenetetramine (urotropine), with antidiabetic drugs (sulfonylurea derivatives), with definin, neodicoumarin, and other indirect anticoagulants.
Streptocide may enhance the effect and/or toxicity of methotrexate as a result of displacing it from protein binding and/or weakening its metabolism.
When used simultaneously with other drugs that cause bone marrow suppression, hemolysis, hepatotoxicity, the development of toxic effects is possible.
Concomitant use with Methenamine (urotropine) is not recommended due to the increased risk of crystalluria with acidic urine.
Phenylbutazone (butadione), salicylates and indomethacin can displace sulfonamides from binding to blood plasma proteins, thereby increasing their concentration in the blood. When used together with para-aminosalicylic acid and barbiturates, the activity of sulfonamides increases; with chloramphenicol - the risk of agranulocytosis increases; with drugs containing para-aminobenzoic acid esters (novocaine, anestezin, dicaine), the antibacterial activity of sulfonamide is inactivated.
Application features.
During treatment with the drug, it is necessary to systematically monitor kidney function, peripheral blood parameters, and blood glucose levels.
During long-term treatment with the drug, it is necessary to periodically perform blood tests (biochemical and general blood tests). Prescribing the drug in insufficient doses or premature discontinuation of the drug may contribute to the increase in the resistance of microorganisms to sulfonamides.
Sulfonamides should not be used to treat infections caused by group A beta-hemolytic streptococcus, as they do not eradicate it and, as a result, cannot prevent complications such as rheumatism and glomerulonephritis.
The drug should be prescribed with caution to patients with chronic heart failure, liver disease and impaired renal function. Streptocide should be prescribed with caution to patients with severe allergic diseases or bronchial asthma, with diseases of the blood system. If signs of a hypersensitivity reaction appear, the drug should be discontinued. In renal failure, cumulation of sulfonamide and its metabolites in the body is possible, which can lead to the development of a toxic effect.
Sulfonamides, including streptocide, should be used with caution in patients with diabetes mellitus, as sulfonamides can affect blood sugar levels. High doses of sulfonamides have a hypoglycemic effect.
Since sulfonamides are bacteriostatic, not bactericidal drugs, a full course of therapy is necessary to avoid recurrence of infection and the development of resistant forms of microorganisms.
Given the similarity of chemical structure, sulfonamides should not be used in people with hypersensitivity to furosemide, thiazide diuretics, carbonic anhydrase inhibitors, and sulfonylurea derivatives.
Patients need to consume sufficient fluids to avoid crystalluria and the development of urolithiasis.
Elderly patients are at increased risk of developing severe adverse skin reactions, hematopoiesis suppression, thrombocytopenic purpura (the latter especially in combination with thiazide diuretics). The drug should be avoided in patients over 65 years of age due to the increased risk of severe adverse reactions.
It is recommended to avoid exposure to direct sunlight and artificial ultraviolet radiation, given the possibility of photosensitization when using sulfonamides.
During treatment, it is necessary to adhere to the dosage regimen, apply the recommended dose at intervals of 24 hours, without skipping a dose of the drug. In case of skipping a dose, double the next dose.
If the signs of the disease do not disappear or, on the contrary, the state of health worsens, or undesirable phenomena occur, it is necessary to suspend the use of the drug and consult a doctor regarding the possibility of further use of the drug.
Use during pregnancy or breastfeeding.
If treatment with the drug is necessary, breastfeeding should be discontinued.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Until the individual reaction to the drug is determined, it is necessary to refrain from driving or working with other mechanisms, since during treatment with sulfonamides, such adverse reactions from the nervous system as dizziness, convulsions, ataxia, drowsiness, depression, and psychosis are possible.
Method of administration and doses.
Take orally during or after meals, drinking 150-200 ml of water. A single dose for adults and children over 12 years of age is 600 mg-1.2 g, a daily dose of 3-6 g. The daily dose is divided into 5 doses. Maximum doses for adults: a single dose of 2 g, a daily dose of 7 g.
A single dose for children aged 3 to 6 years is 300 mg, from 6 to 12 years - 300-600 mg. The frequency of administration for children is 4-6 times a day.
The maximum daily dose for children is 0.9-2.4 g.
The duration of treatment is determined by the doctor individually, depending on the severity and course of the disease, the localization of the process, and the effectiveness of therapy.
Children.
Used for children aged 3 years and over.
Overdose.
Possible increased side effects.
In case of overdose, anorexia (lack of appetite), nausea, vomiting, colic-like pain, headache, drowsiness, dizziness, fainting may occur. With prolonged use, fever, hematuria, crystalluria, cyanosis, tachycardia, paresthesias, diarrhea, cholestasis, renal failure with anuria, toxic hepatitis, leukopenia, agranulocytosis are possible.
Treatment. In case of overdose, it is recommended to consult a doctor. Symptomatic therapy. Before providing medical care, wash the stomach with a 2% solution of sodium bicarbonate and take a suspension of activated charcoal or other enterosorbents. Drinking plenty of fluids, forced diuresis, hemodialysis are indicated.
Adverse reactions.
From the blood system: leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, hypoprothrombinemia, eosinophilia, hemolytic anemia with glucose-6-phosphate dehydrogenase deficiency.
Cardiovascular system: tachycardia, myocarditis.
Nervous system: headache; neurological reactions, including aseptic meningitis; ataxia; slight intracranial hypotension; convulsions; dizziness; drowsiness/insomnia; feeling of fatigue; depression; peripheral or optic neuropathies; visual disturbances; psychosis; depressed state; paresthesia.
On the part of the respiratory system: pulmonary infiltrates, fibrosing alveolitis.
Gastrointestinal tract: thirst, dry mouth, dyspeptic phenomena, nausea, vomiting, diarrhea, anorexia, pancreatitis, pseudomembranous colitis.
On the part of the hepatobiliary system: increased activity of liver enzymes (alanine transaminase, aspartate transaminase, alkaline phosphatase), cholestatic hepatitis, hepatonecrosis, hepatomegaly, jaundice, cholestasis.
On the part of the urinary system: change in urine color (rich yellow-brown color), crystalluria with an acidic urine reaction; nephrotoxic reactions are possible: interstitial nephritis, tubular necrosis, renal failure, hematuria, shock kidney with anuria.
Skin and subcutaneous tissue disorders: skin hyperemia, skin rash (including erythematous-squamous, papular), itching, urticaria, allergic dermatitis, photosensitivity, exfoliative dermatitis, erythema nodosum, cyanosis.
Allergic reactions: toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, systemic lupus erythematosus, serum sickness, anaphylactic reactions, angioedema, rhinitis.
General disorders: drug-induced fever, pain in the right hypochondrium and lower back.
Others: difficulty breathing, periarteritis nodosa, hypothyroidism, hypoglycemia. In rare cases, hypothyroidism may develop.
Expiration date.
5 years.
Storage conditions.
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging.
10 tablets in blisters.
Vacation category.
According to the recipe.
Producer.
PJSC Lubnyfarm.
Location of the manufacturer and address of its place of business.
Ukraine, 37500, Poltava region, M lubny, Barvinkovy St., 16.
